The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk

Thrombosis Research

Volumn 122, Issue 6, 2008, Pages 736-742

  Tsantes, Argirios E ^a   Nikolopoulos, Georgios K ^b   Bagos, Pantelis G ^c   Bonovas, Stefanos ^b   Kopterides, Petros ^d   Vaiopoulos, Georgios ^e  

^a Blood Bank Unit   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

4G 5G polymorphism; PAI 1; Thrombotic risk

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALLELE; ARTERY THROMBOSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

BRAIN ISCHEMIA; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 52249094419     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.09.005     Document Type: Review

References (56)

1. Stiko A., Hervio L., and Loskutoff D.J. Plasminogen activator inhibitors. In: Colleman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed (2001), Pa: Lippincott Williams and Wilkins, Philadelphia 975-1002
2. Smith E.B. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 19 (1998) 39-43
3. Loskutoff D.J., and Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 18 (1988) 1-6
4. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 2 (1996) 800-803
5. Alessi M.C., Juhan-Vsgue I., Kooistra T., Declerck P.J., and Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line HEP G2. Thromb Haemost 60 (1998) 491-494
6. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk for myocardial infarction or sudden death in patients with angina pectoris. Circulation 94 (1996) 2057-2063
7. Nordt T.K., Klassen K.J., Schneider D.J., and Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 13 (1993) 1822-1828
8. Irigoyen J.P., Munoz C.P., Montero L., Koziczak M., and Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56 (1999) 104-132
9. Klinger K.W., Winqvist R., Riccio A., Andreasen P.A., Sartorio R., Nielsen L.S., et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84 (1987) 8548-8552
10. Dawson S., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
11. Burzotta F., Di Castelnuovo A., Amore C., D' Orazio A., Di Bitondo R., Donati M.B., et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 79 (1998) 354-358
12. Festa A., D'Agostino R., Rich S.S., Jenny N.S., Tracy R.P., and Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics and non-Hispanics whites: the Insulin Resistance Atherosclerosis Study. Circulation 107 (2003) 2422-2427
13. Lane D.A., and Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95 (2000) 1517-1532
14. Hoekstra T., Geleijnse J.M., Schouten E.G., and Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91 (2004) 861-872
15. Ye Z., Liu E.H.C., Higgins J.P.T., Keanvey B.D., Lowe G.D.O., Collins R., et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66155 cases and 91307 controls. Lancet 367 (2006) 651-658
16. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Tsiara C., Kapsimali V., Travlou A., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 18 (2007) 497-504
17. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Rapti E., Mantzios G., Kapsimali V., et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis: a meta-analysis. Thromb Haemost 97 (2007) 907-913
18. Boekholdt S.M., Bijsterveld N.R., Moons A.H.M., Levi M., Buller H.R., and Peters R.J.G. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 104 (2001) 3063-3068
19. Boncoraglio G.B., Bodini A., Brambilla C., Carriero M.R., Ciusani E., and Parati E.A. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis 22 (2006) 191-195
20. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor-1 and insulin resistance. Diabet Metab Res Rev 16 (2000) 192-201
21. Brown N.J., Murphey L.J., Srikuma L., Koschachuhanan N., Williams G.H., and Vaughan D.E. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 21 (2001) 1071-1077
22. Sartori M.T., Vettor R., De-Pergola G., De Mitrio V., Saggiorato G., Della Mea P., et al. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients-Influence of fat distribution and insulin resistance. Thromb Haemost 86 (2001) 1161-1169
23. Iacoviello L., Burzotta F., Di Castelnuovo A., Zito F., Marchioli R., and Donati M.B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 80 (1998) 1029-1030
24. Iwai N., Shimoike H., Nakamura Y., Tamaki S., and Kinoshita M. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 136 (1998) 109-114
25. Bang C.O., Park H.K., Ahn M.Y., Shin H.K., Hwang K.Y., and Hong S.Y. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 11 (2001) 294-299
26. Wiklund P.G., Nilsson L., Nilsson Ardnor S., Eriksson P., Johansson L., Stegmayr B., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke. Replicated findings in two nested case-control studies based on independent cohorts. Stroke 36 (2005) 1661-1665
27. Roest M., Van Der Schouw Y.T., Banga J.D., Tempelman M.J., De Groot P.G., Sixma J.J., et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101 (2000) 67-70
28. Endler G., Lalouschek W., Exner M., Mitterbauer G., Haring D., and Mannhalter C. The 4G/4G genotype at nucleotide position - 675 in the promoter region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 110 (2000) 469-471
29. Hindorff L.A., Schwartz S.M., Siscovick D.A., Psaty B.M., Longstreth Jr. W.T., and Reiner A.P. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9 (2002) 131-137
30. Hoekstra T., Geleijnse J.M., Kluft C., Giltay E.J., Kok F.J., and Schouten E.G. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 34 (2003) 2822-2829
31. Catto A.J., Carter A.M., Stickland M., Bamford J.M., Davies J.A., and Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorhism and levels in subjects with cerebrovascular disease. Thromb Haemost 77 (1997) 730-734
32. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Stroke 24 (1993) 35-41
33. Vergouwen M.D.I., Frijns C.J.M., Roos Y.B., Rinkel G.J.E., Baas F., and Vermeulen M. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurismal subarachnoid hemorrhage. Stroke 35 (2004) 1280-1283
34. Sirgo G., Perez-Vela J.L., Morales P., Del Ray M., Vendrell J., Gutierrez C., et al. Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Med 32 (2006) 668-675
35. Benchenane K., Lopez-Atalaya J.P., Fernadez-Monreal M., Touzani O., and Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 27 (2004) 155-160
36. Heymans S., Luttun A., Nuyens D., Theilmeier G., Greemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5 (1999) 1135-1142
37. Grubic N., Stegnar M., Peternel P., Kaider A., and Binder B.R. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84 (1996) 431-443
38. Ridker P.M., Hennekens C.H., Lindpainter K., Stamfer M.J., and Miletich J.P. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95 (1997) 59-62
39. Mansilha A., Araujo F., Severo M., et al. The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and deep venous thrombosis in young people. Phlebology 20 (2005) 48-52
40. Segui R., Estelles A., Mira Y., Espana F., Villa P., Falco C., et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111 (2000) 122-128
41. Akar N., Yilmaz E., Akar E., Avcu F., Yalcin A., and Cin Sl. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients within and without FV1691 G-A. Thromb Res 97 (2000) 227-230
42. Sartori M.T., Danesin C., Saggiorato G., Tormene D., Simioni P., Spiezia L., et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb/Hemost 9 (2003) 299-307
43. Tassies D., Espinosa G., Munoz-Rodriguez F.J., Freire C., Cervera R., Monteagudo J., et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43 (2000) 2349-2358
44. Morange P.E., Henry M., Tregouet D., Granel B., Aillaud M.F., Alessi M.C., et al. The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20 (2000) 1387-1391
45. Gurgey A., Balta G., and Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease. Blood Coagul Fibrinolysis 14 (2003) 121-124
46. Yasuda S., Tsutsumi A., Atsumi T., Bertolaccini M.L., Ichikawa K., Khamashta M.A., et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 2 (2002) 1192-1197
47. van Hinsbergh V.W.M., Kooistra T., van den Bergh E.A., Princen H.G.M., Fiers W., and Emeis J.J. TNF increases the production of PAI in human endothelial cells in vitro and rats in vivo. Blood 72 (1988) 1467-1473
48. Dawson S., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
49. Hermans P.W., Hibberd M.L., Booy R., Daramola O., Hazelzet J.A., de Groot R., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354 (1999) 556-560
50. Geishofer G., Binder A., Muller M., Zohrer B., Resch B., Muller W., et al. Central European Meningococcal Genetic Study Group. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164 (2005) 486-490
51. Haralambous E., Hibberd M.L., Hermans P.W., Ninis N., Nadel S., and Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity and outcome of meningococcal disease in Caucasian children. Crit Care Med 31 (2003) 2788-2793
52. Menges T., Hermans P.W., Little S.G., Langefeld T., Boning O., Engel J., et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 357 (2001) 1096-1097
53. Kornelisse R.F., Hazelzet J.A., Savelkoul H.F., Hop W.C., Suur M.H., Borsboom A.N., et al. The relationship between plasminogen-activator-inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 173 (1996) 1148-1156
54. Mesters R.M., Florke N., Ostermann H., and Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of patients with sepsis. Thromb Haemost 75 (1996) 902-907
55. Bertozzi P., Astedt B., Zenzius L., Lynch K., LeMaire F., Zapol W., and Chapman H.A. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 322 (1990) 890-897
56. Idell S., James K.K., Levin E.G., Schwartz B.S., Manchanda N., Maunder R.J., et al. Local abnormalities in coagulation and fibrinolytic pathways predisposed to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84 (1989) 695-705